PDCD1 and cancer: To this aim, we established syngeneic orthotopic tumors derived from KP cancer cells, and we tested whether the treatment with tiplaxtinin, an orally available and selective PAI-1 inhibitor (33), could improve the efficacy of a combination therapy using standard chemotherapy (gemcitabine) and immunotherapy with PD-1 (programmed cell death protein 1) antagonists (anti-PD1) (Fig. 6A).